Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression
Author:
Affiliation:
1. Division of Hematology and Oncology Georgetown University School of Medicine Washington, DC, USA
2. Myeloma Division, John Theurer Cancer Center at Hackensack Meridian School of Medicine Hackensack, NJ
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.2010065
Reference6 articles.
1. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)
2. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
3. Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
4. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
5. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11
2. Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression;Leukemia & Lymphoma;2024-08
3. Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review;Frontiers in Oncology;2024-07-10
4. Current Status on Management of Primary Plasma Cell Leukemia;Current Oncology Reports;2024-07-02
5. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study;Hematology;2023-09-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3